Y Loriot
Overview
Explore the profile of Y Loriot including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
68
Citations
1382
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Powles T, Tagawa S, Vulsteke C, Gross-Goupil M, Park S, Necchi A, et al.
Ann Oncol
. 2025 Feb;
PMID: 39934055
Background: Sacituzumab govitecan (SG), a Trop-2-directed antibody-drug conjugate, demonstrated efficacy and manageable toxicity in the phase II TROPHY-U-01 study in pretreated advanced urothelial carcinoma (aUC). We report the results from...
2.
Rosenberg J, Galsky M, Powles T, Petrylak D, Bellmunt J, Loriot Y, et al.
ESMO Open
. 2024 Dec;
9(12):103972.
PMID: 39642637
Background: The IMvigor210 trial demonstrated clinical benefit and manageable toxicity with atezolizumab monotherapy [anti-programmed death-ligand 1 (PD-L1)] in patients with metastatic urothelial carcinoma (UC) in primary analyses. Final efficacy and...
3.
Powles T, Bellmunt J, Comperat E, De Santis M, Huddart R, Loriot Y, et al.
Ann Oncol
. 2024 Mar;
35(6):485-490.
PMID: 38490358
No abstract available.
4.
Loriot Y, Petrylak D, Rezazadeh Kalebasty A, Flechon A, Jain R, Gupta S, et al.
Ann Oncol
. 2024 Jan;
35(4):392-401.
PMID: 38244927
Background: Sacituzumab govitecan (SG) is a Trop-2-directed antibody-drug conjugate containing cytotoxic SN-38, the active metabolite of irinotecan. SG received accelerated US Food and Drug Administration approval for locally advanced (LA)...
5.
Necchi A, Pouessel D, Leibowitz R, Gupta S, Flechon A, Garcia-Donas J, et al.
Ann Oncol
. 2023 Nov;
35(2):200-210.
PMID: 37956738
Background: Fibroblast growth factor receptor 3 (FGFR3) alterations are oncogenic drivers of urothelial carcinoma (UC). Pemigatinib is a selective, oral inhibitor of FGFR1-3 with antitumor activity. We report the efficacy...
6.
Blay J, Cropet C, Mansard S, Loriot Y, de la Fouchardiere C, Haroche J, et al.
ESMO Open
. 2023 Nov;
8(6):102038.
PMID: 37922690
Background: BRAF inhibitors are approved in BRAF-mutated metastatic melanoma, non-small-cell lung cancer (NSCLC), Erdheim-Chester disease (ECD), and thyroid cancer. We report here the efficacy, safety, and long-term results of single-agent...
7.
Siefker-Radtke A, Matsubara N, Park S, Huddart R, Burgess E, Ozguroglu M, et al.
Ann Oncol
. 2023 Oct;
35(1):107-117.
PMID: 37871702
Background: Erdafitinib is an oral pan-fibroblast growth factor receptor (FGFR) tyrosine kinase inhibitor approved to treat locally advanced/metastatic urothelial carcinoma (mUC) in patients with susceptible FGFR3/2 alterations (FGFRalt) who progressed...
8.
Catto J, Tran B, Roupret M, Gschwend J, Loriot Y, Nishiyama H, et al.
Ann Oncol
. 2023 Oct;
35(1):98-106.
PMID: 37871701
Background: Treatment options are limited for patients with high-risk non-muscle-invasive bladder cancer (NMIBC) with disease recurrence after bacillus Calmette-Guérin (BCG) treatment and who are ineligible for/refuse radical cystectomy. FGFR alterations...
9.
Rosenberg J, Powles T, Sonpavde G, Loriot Y, Duran I, Lee J, et al.
Ann Oncol
. 2023 Sep;
34(11):1047-1054.
PMID: 37678672
Introduction: This exploratory analysis evaluated efficacy and safety data for enfortumab vedotin versus chemotherapy over a median follow-up of ∼2 years from EV-301. Materials And Methods: Patients with locally advanced/metastatic...
10.
Valery M, Saleh K, Ecea R, Michot J, Ribrag V, Fizazi K, et al.
Cancer Chemother Pharmacol
. 2023 Jun;
92(3):229-233.
PMID: 37354233
Background: Cytokine release syndrome (CRS) is a common adverse event of CAR T cell or bispecific antibody (bsAb) therapy. Anti-IL6/IL6R drugs are used in the management of auto-immune diseases. Some...